|Day Low/High||118.73 / 121.43|
|52 Wk Low/High||109.12 / 162.00|
This biotech company is trading at a bargain compared to its peer group.
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that the U.
Investors are deciding what to make of an impending overhaul of the American health care system in the wake of legislative progress out of Washington.
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that management will present at two upcoming investor conferences: Cowen and Company 37th Annual Health Care Conference in Boston on Monday, March 6, 2017...
Less than two years later, Alexion is not getting the bang for the mega-bucks it put up for Synageva.
Alexion paid $8.4 billion to acquire Synageva in hopes that its leading rare disease drug would become a billion-dollar product.
Progenics, Alexion and BioCryst were among the biotech stock movers in premarket trading on Thursday.
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced financial results for the fourth quarter and full year of 2016.
Fed Chair Janet Yellen will give her two-day semiannual monetary policy testimony, while major economic data will drive markets.
Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2016 on Thursday, February 16, 2017 before the US...
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C.
This drug maker has risen more than 17% this year. But investors may want to say cautious, unless they are super-aggressive.
The $5.2 billion takeout of Ariad Pharma was the biggest news from the closely followed healthcare conference.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the Company has submitted marketing applications to the U.
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of...
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the U.
Alexion Pharmaceuticals (Nasdaq: ALXN) today announced that management will present at the 35th Annual J.
Every January at 'JPM,' investors take the pulse of the biotech industry for the coming year.
Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) announced today that it has filed with the Securities and Exchange Commission its Form 10-Q for the third quarter ended September 30, 2016.
Adam Feuerstein compiles a list of questions, thoughts, declarations, catalysts and observations about biotech stocks to help investors prepare for the year ahead.